Dasatinib-Induced Pulmonary Arterial Hypertension: A Case Report

• Main Authors: Liu R, Tang Y, Fu T, Zhou J, Ma L, Yuan J, Xu O
• Format: Article
• Language: English
• Published: Dove Medical Press 2021-08-01
• Series: Research Reports in Clinical Cardiology
• Subjects: dasatinib-induced pulmonary arterial hypertension; right heart failure; pulmonary vasodilator; tyrosine kinase inhibitor
• Online Access: https://www.dovepress.com/dasatinib-induced-pulmonary-arterial-hypertension-a-case-report-peer-reviewed-fulltext-article-RRCC

Ru Liu,1,2 Yinjiang Tang,2 Ting Fu,2 Jianli Zhou,2 Lijiao Ma,2 Jinqing Yuan,1 Ou Xu2 1Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Pulmonary Vascular and General Medicine, Fuwai Yunnan Cardiovascular Hospital, Yunnan Provincial Cardiovascular Disease Clinical Medical Center, Kunming, Yunnan Province, People’s Republic of ChinaCorrespondence: Ou XuFuwai Yunnan Cardiovascular Hospital, Yunnan Provincial Cardiovascular Disease Clinical Medical Center, No. 528 North Shahe Road, Wuhua District, Kunming, 650102, People’s Republic of ChinaTel [phone]Email [e-mail] YuanFuwai Hospital, Chinese Academy of Medical Sciences, No. 167 North Lishi Road, Xicheng District, Beijing, 100037, People’s Republic of ChinaTel [phone]Email [e-mail]: Dasatinib was identified to be associated with pulmonary arterial hypertension, also called dasatinib-induced pulmonary arterial hypertension. There was still little data on clinical characteristics of this rare but severe complication during hematological therapy in China. A 40-year-old female with worsening dyspnoea was diagnosed with severe pulmonary arterial hypertension and progressive right heart failure, and stabilized by standardized comprehensive management, including replacement of other tyrosine kinase inhibitor, administration of pulmonary vasodilators according to the right-heart catheterization-based risk stratification and traditional anti-heart failure drug therapy. Our case suggests that dasatinib-induced pulmonary arterial hypertension may be partially reversible, with a relatively good prognosis under formal target therapy of pulmonary arterial hypertension, providing new insight into its treatment algorithm.Keywords: dasatinib-induced pulmonary arterial hypertension, right heart failure, pulmonary vasodilator, tyrosine kinase inhibitor